Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Am J Gastroenterol. 2021 Dec 1;116(12):2446–2454. doi: 10.14309/ajg.0000000000001527

Table 3a:

Rate ratio for time on CFTR modulator versus time not on CFTR modulator among full study population (n=10,417)

Model Pancreas Sufficient Cystic
Fibrosis (PS-CF)
Pancreas Insufficient Cystic
Fibrosis (PI-CF)
Observed 0.33 (0.10, 1.11), p=0.07 0.38 (0.16, 0.89), p=0.03
Multivariable (adjusted)* 0.32 (0.10, 0.99), p=0.05 0.37 (0.15, 0.92), p=0.03
*

Adjusted for age (continuous), sex, Charlson comorbidity index, and geographic region